L R Zacharski

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy
    Leo R Zacharski
    Research Service 151, VA Medical Center, White River Junction, VT 05009, USA
    Cancer Lett 186:1-9. 2002
  2. ncbi Atherosclerosis: a manifestation of chronic iron toxicity?
    Leo R Zacharski
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Vasc Med 8:153-5. 2003
  3. ncbi Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma
    Leo R Zacharski
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, VA Medical Center, 215 North Main Street, White River Junction, Vermont 05009, USA
    Expert Rev Cardiovasc Ther 2:777-84. 2004
  4. ncbi Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST)
    Leo R Zacharski
    Department of Veterans Affairs Medical Centers, White River Junction, VT 05001, USA
    Am Heart J 148:386-92. 2004
  5. ncbi Warfarin versus low-molecular-weight heparin therapy in cancer patients
    Leo R Zacharski
    VA Medical and Regional Office Center, 215 North Main Street, White River Junction, Vermont 05009, USA
    Oncologist 10:72-9. 2005
  6. ncbi Hypercoagulability preceding cancer. The iron hypothesis
    L R Zacharski
    VA Hospital, White River Junction, VT, USA
    J Thromb Haemost 3:585-8. 2005
  7. ncbi Commentary on "The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis"
    Leo R Zacharski
    Department of Medicine, Dartmouth Medical School, Lebanon, NH 03756, USA
    Free Radic Biol Med 40:1700-1. 2006
  8. ncbi Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial
    Leo R Zacharski
    White River Junction VA Medical Center, Research Service, Department of Veterans Affairs Medical Center, White River Junction, VT 05001, USA
    JAMA 297:603-10. 2007
  9. ncbi Venous thromboembolism prevention in cancer patients: the search for common antecedents
    Leo R Zacharski
    Dartmouth Hitchcock Medical Center, Department of Medicine, Section of Hematology Oncology, Lebanon, NH 03756, USA
    Expert Opin Pharmacother 8:2117-25. 2007
  10. ncbi The heparins and cancer
    Leo R Zacharski
    The Department of Veterans Affairs Medical Center, White River Jct, Vermont 05009, USA
    Curr Opin Pulm Med 8:379-82. 2002

Detail Information

Publications44

  1. ncbi Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy
    Leo R Zacharski
    Research Service 151, VA Medical Center, White River Junction, VT 05009, USA
    Cancer Lett 186:1-9. 2002
    ....
  2. ncbi Atherosclerosis: a manifestation of chronic iron toxicity?
    Leo R Zacharski
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Vasc Med 8:153-5. 2003
  3. ncbi Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma
    Leo R Zacharski
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, VA Medical Center, 215 North Main Street, White River Junction, Vermont 05009, USA
    Expert Rev Cardiovasc Ther 2:777-84. 2004
    ..These data suggest that drugs that are well-known in the field of vascular medicine may find a role in the treatment of hepatocellular carcinoma, a common tumor type that has resisted containment by other means...
  4. ncbi Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST)
    Leo R Zacharski
    Department of Veterans Affairs Medical Centers, White River Junction, VT 05001, USA
    Am Heart J 148:386-92. 2004
    ....
  5. ncbi Warfarin versus low-molecular-weight heparin therapy in cancer patients
    Leo R Zacharski
    VA Medical and Regional Office Center, 215 North Main Street, White River Junction, Vermont 05009, USA
    Oncologist 10:72-9. 2005
    ..Further evaluation of the LMWHs for effects on cancer outcome is indicated...
  6. ncbi Hypercoagulability preceding cancer. The iron hypothesis
    L R Zacharski
    VA Hospital, White River Junction, VT, USA
    J Thromb Haemost 3:585-8. 2005
  7. ncbi Commentary on "The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis"
    Leo R Zacharski
    Department of Medicine, Dartmouth Medical School, Lebanon, NH 03756, USA
    Free Radic Biol Med 40:1700-1. 2006
  8. ncbi Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial
    Leo R Zacharski
    White River Junction VA Medical Center, Research Service, Department of Veterans Affairs Medical Center, White River Junction, VT 05001, USA
    JAMA 297:603-10. 2007
    ..Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical-mediated oxidative stress...
  9. ncbi Venous thromboembolism prevention in cancer patients: the search for common antecedents
    Leo R Zacharski
    Dartmouth Hitchcock Medical Center, Department of Medicine, Section of Hematology Oncology, Lebanon, NH 03756, USA
    Expert Opin Pharmacother 8:2117-25. 2007
    ..Increasing understanding of the interplay between the coagulation mechanism and neoplasia has yielded clues to the upstream origins of both, which may lead to experimental intervention potentially capable of preventing both...
  10. ncbi The heparins and cancer
    Leo R Zacharski
    The Department of Veterans Affairs Medical Center, White River Jct, Vermont 05009, USA
    Curr Opin Pulm Med 8:379-82. 2002
    ..HLGAGs may be a fundamental intermediate in the abnormal growth regulation characteristic of neoplasia that is susceptible to targeted intervention...
  11. ncbi Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial
    Leo R Zacharski
    Research Service 151, White River Junction VA Medical Center, Department of Veterans Affairs Medical Center, 215 North Hartland Road, White River Junction, VT 05009, USA
    J Natl Cancer Inst 100:996-1002. 2008
    ..Excess iron has been implicated in cancer risk through increased iron-catalyzed free radical-mediated oxidative stress...
  12. ncbi The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease
    L R Zacharski
    Department of Veterans Association Medical Centers, White River Junction, VT 05009 0001, USA
    Am Heart J 139:337-45. 2000
    ....
  13. ncbi Low-molecular-weight heparin and cancer
    L R Zacharski
    VA Medical and Regional Office Center, White River Junction, Vermont 05009, USA
    Semin Thromb Hemost 26:69-77. 2000
    ....
  14. ncbi Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A
    L R Zacharski
    Section of Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Haemophilia 16:726-30. 2010
    ....
  15. ncbi Treatment of malignancy by activation of the plasminogen system
    Leo R Zacharski
    VA Medical and Regional Office Center, White River Junction, Vermont 05009, USA
    Semin Thromb Hemost 28:5-18. 2002
    ..These observations suggest novel approaches to the experimental therapy of cancer...
  16. ncbi Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy
    Leo R Zacharski
    Vermont and Dartmouth Medical School, HB 7900, Lebanon, NH 03755, USA
    IDrugs 6:1036-8. 2003
  17. ncbi Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease
    Leo R Zacharski
    Department of Veterans Affairs Medical Center, White River Jct, VT 05009, USA
    Am Heart J 162:949-957.e1. 2011
    ..The mechanism of the age-specific effect was explored...
  18. ncbi The coagulation system as a target for experimental therapy of human gliomas
    J T Loynes
    Section of Hematology Oncology, DartmouthHitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03257, USA
    Expert Opin Ther Targets 7:399-404. 2003
    ..This approach offers the prospect of a novel treatment for this devastating tumour type that does not share the toxicities of conventional cancer therapies...
  19. ncbi Low-molecular-weight heparin in oncology
    Leo R Zacharski
    VA Medical and Regional Office Center, Vermont, USA
    Anticancer Res 23:2789-93. 2003
    ..Outstanding issues relating to thromboprophylaxis and treatment of VTE in patients with cancer and the clinical trials that may resolve these issues are also highlighted...
  20. ncbi Getting the iron out: phlebotomy for Alzheimer's disease?
    Barney E Dwyer
    Research Service, Department of Veterans Affairs Medical Center, White River Junction, VT 05009 0001, United States
    Med Hypotheses 72:504-9. 2009
    ..Testing this hypothesis could provide valuable insight into the causation of AD and suggest novel preventive and treatment strategies...
  21. ncbi Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients
    Cocav A Engman
    Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    J Natl Compr Canc Netw 6:637-45. 2008
    ..Further clinical research is needed to evaluate the potential survival benefits of LMWH therapy in patients with cancer...
  22. ncbi Coagulation biology in glioma pathogenesis: a missing link?
    C E Fadul
    Section of Hematology Oncology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH and VA Hospital, White River Jct, VT, USA
    J Thromb Haemost 3:1915-6. 2005
  23. ncbi Successful donation and transplantation of multiple organs after fatal poisoning with brodifacoum, a long-acting anticoagulant rodenticide: case report
    D L Ornstein
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Transplantation 67:475-8. 1999
    ..In this report, we describe a case of multiple organ donation from a previously healthy individual who died from poisoning with the long-acting anticoagulant rodenticide, brodifacoum...
  24. ncbi Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?
    L R Zacharski
    Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
    J Thromb Haemost 3:424-7. 2005
  25. ncbi Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer
    Leo R Zacharski
    Veterans Administration Medical Center, White River Junction, Vermont 05001, USA
    Semin Thromb Hemost 29:239-46. 2003
    ..Although limited experience to date in human disease has supported these concepts, resolution of cause-and-effect relationships will require performance of additional rationally designed clinical trials...
  26. ncbi The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease
    D J Solet
    Section of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Am J Med 111:45-53. 2001
    ..ADP inhibitors, by blocking an alternate pathway of platelet activation, are slightly more effective than aspirin in reducing cardiovascular events...
  27. ncbi Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence
    Richard H Cosgrove
    Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan 48201, USA
    Semin Thromb Hemost 28:79-87. 2002
    ..Proposals for the most likely targets of the effective heparins include enzyme interaction, cellular growth modifications, and antiangiogenesis...
  28. ncbi Activity of heparins in experimental models of malignancy: Possible explanations for anticancer effects in humans
    Deborah L Ornstein
    59th MDW MMIH, Wilford Hall Medical Center, 2200 Bergquist Drive, Lackland Air Force Base, San Antonio, TX 78236, USA
    Clin Hemorheol Microcirc 26:33-40. 2002
    ....
  29. ncbi A rebuttal: vitamin K antagonists and cancer survival
    Leo R Zacharski
    Thromb Haemost 88:173-4; author reply 175. 2002
  30. ncbi Heparin as an anticancer therapeutic
    Leo R Zacharski
    Hamilton Health Sciences Henderson Hospital, 711 Concession Street, Hamilton, ON L8V1C3, Canada
    Expert Opin Investig Drugs 17:1029-37. 2008
    ....
  31. ncbi Cytokine signatures in atherosclerotic claudicants
    Ralph G DePalma
    Veterans Affairs Central Office, 20420, Washington, DC 20040, USA
    J Surg Res 111:215-21. 2003
    ..Iron accumulation and inflammation may affect atherosclerosis. This study intended to define a cytokine signature in atherosclerotic claudicants and to determine whether reduction in serum ferritin by phlebotomy influenced this pattern...
  32. ncbi Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes
    Duk Hee Lee
    Division of Preventive Medicine, School of Medicine, Kyungpook National University, Jung Gu, Daegu, South Korea
    Am Heart J 151:1247.e1-7. 2006
    ....
  33. ncbi Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer
    Marek Z Wojtukiewicz
    Department of Oncology, Medical Academy, Bialystok, Poland
    Semin Thromb Hemost 29:291-300. 2003
    ..Colocalization of VEGF with hemostatic proteins suggests that they may cooperate in the pathogenesis of gastric cancer...
  34. ncbi Cancer and venous thromboembolism: a multidisciplinary approach
    Henrik T Sørensen
    Department of Clinical Epidemiology, Aarhus and Aalborg University Hospitals, Denmark
    Clin Lab 49:615-23. 2003
    ..However, the clinical implications of these findings must await properly designed and conducted randomized clinical trials...
  35. ncbi Interfering with hemostatic system components: possible new approaches to antiangiogenic therapy
    Marek Z Wojtukiewicz
    Department of Oncology, Medical University, Bialystok, Poland
    Semin Thromb Hemost 30:145-56. 2004
    ..Rather it is aimed at restoring the normal state by modulating the dysregulated interaction of tumor cells with their environment that is characteristic of cancer...
  36. ncbi Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer
    Marek Z Wojtukiewicz
    Department of Oncology, Medical Academy, Bialystok, Poland
    Semin Thromb Hemost 29:317-20. 2003
    ..Trace staining was found for u-PA receptor (u-PAR) in differentiated tumor cells. The significance of coagulation and fibrinolytic pathways present in situ to the economy of laryngeal carcinoma remains to be determined...
  37. ncbi Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study
    Ralph G DePalma
    Department of Veterans Affairs, Washington, DC 20420, USA
    Vascular 14:193-200. 2006
    ..Unexpectedly, serum inflammatory cytokine IL-6 levels were significantly higher in PAD subjects receiving statins. There was no difference in measured inflammatory markers in PAD subjects with concomitant CAD...
  38. ncbi Bloodletting: past and present
    Ralph G DePalma
    Patient Care Services VA Central Office, Washington, DC, USA
    J Am Coll Surg 205:132-44. 2007
  39. ncbi The coagulation system as a target for the treatment of human gliomas
    Deborah L Ornstein
    Special Hematology and Coagulation Laboratory, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas 78236, USA
    Semin Thromb Hemost 28:19-28. 2002
    ..This article reviews the implications of coagulation activation in human gliomas and provides a rationale for clinical testing of anticoagulants as part of a treatment strategy for this devastating human cancer...
  40. ncbi Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells
    Deborah L Ornstein
    Department of Laboratory Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Nutr Cancer 58:115-26. 2007
    ..Our data indicate that one mechanism by which iron may stimulate uPA production is through the generation of intracellular ROI and activation of NF-kappaB-mediated signaling pathways...
  41. ncbi Regression of metastatic non-small cell lung cancer with low molecular weight heparin
    James T Loynes
    Thromb Haemost 88:686. 2002
  42. ncbi Heparin treatment of malignancy: the case for clinical trials in colon cancer
    Leo R Zacharski
    Thromb Res 110:213-4. 2003
  43. ncbi Evaluating the role of serine protease inhibition in the management of tumor micrometastases
    Joe B Putnam
    University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:9-30; quiz 31-2. 2003
  44. ncbi The functions of plasminogen activator inhibitor-1: do we have all the pieces of PAI?
    Mary Jo Mulligan-Kehoe
    Thromb Res 117:483-6. 2006